Atherosclerosis
Volume 169, Issue 1 , Pages 113-120 , July 2003

The safety and immunogenicity of a CETP vaccine in healthy adults

  • Michael H. Davidson

      Affiliations

    • Rush-Presbyterian-St. Luke's Medical Center, Chicago Center for Clinical Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-312-563-2011; fax: +1-312-563-4417
    • ,
  • Kevin Maki

      Affiliations

    • Rush-Presbyterian-St. Luke's Medical Center, Chicago Center for Clinical Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA
    • ,
  • Denise Umporowicz

      Affiliations

    • Rush-Presbyterian-St. Luke's Medical Center, Chicago Center for Clinical Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA
    • ,
  • Alistair Wheeler

      Affiliations

    • AVANT Immunotherapeutics, Inc., Needham, MA, USA
    • ,
  • Charles Rittershaus

      Affiliations

    • AVANT Immunotherapeutics, Inc., Needham, MA, USA
    • ,
  • Una Ryan

      Affiliations

    • AVANT Immunotherapeutics, Inc., Needham, MA, USA

Received 20 September 2002 ,Revised 20 February 2003 ,Accepted 7 March 2003.

References 

  1. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. J. Am. Med. Assoc. 2002;288:462–467
  2. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486–97.
  3. Tall AR. Plasma cholesteryl ester transfer protein and high-density lipoproteins: new insights from molecular genetic studies. J. Intern. Med. 1995;237:5–12
  4. Tall AR. An overview of reverse cholesterol transport. Eur. Heart J. 1998;19(Suppl. A):A31–A35
  5. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The regression growth evaluation statin study group. New Engl. J. Med. 1998;338:86–93
  6. Whitlock ME, Swenson TL, Ramakrishnan R, Leonard MT, Marcel YL, Milne RW, et al. Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit. Effects on lipoprotein composition and high density lipoprotein cholesteryl ester metabolism. J. Clin. Invest. 1989;84:129–137
  7. Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, Whitlock ME, et al  Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature. 1989;342:448–451
  8. Rittershaus CW, Miller DP, Thomas LJ, Picard MD, Honan CM, Emmett CD, et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2000;20:2106–2112
  9. Delves PJ, Lund T, Roitt IM. Antifertility vaccines. Trends Immunol. 2002;23:213–219
  10. Talwar GP, Singh OM, Gupta SK, Hasnain SE, Pal R, Majumbar SS, et al. The HSD-hCG vaccine prevents pregnancy in women: feasibility study of a reversible safe contraceptive vaccine. Am. J. Reprod. Immunol. 1997;37:153–160
  11. Brett BT, Smith SC, Bouvier CV, Michaeli D, Hochhauser D, Davidson BR, et al. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J. Clin. Oncol. 2002;20:4225–4231
  12. Data on file. AVANT Immunotherapeutics, Inc., Needham, MA.
  13. Hesler CB, Tall AR, Swenson TL, Weech PK, Marcel YL, Milne RW. Monoclonal antibodies to the Mr 74 000 cholesteryl ester transfer protein neutralize all of the cholesteryl ester and triglyceride transfer activities in human plasma. J. Biol. Chem. 1988;263:5020–5023
  14. Wang S, Deng L, Milne RW, Tall AR. Identification of a sequence within the C-terminal 26 amino acids of cholesteryl ester transfer protein responsible for binding a neutralizing monoclonal antibody and necessary for neutral lipid transfer activity. J. Biol. Chem. 1992;267:17487–17490
  15. Wang S, Kussie P, Deng L, Tall AR. Defective binding of neutral lipids by a carboxyl-terminal deletion mutant of cholesteryl ester transfer protein. J. Biol. Chem. 1995;270:612–618
  16. Tall AR. Plasma cholesteryl ester transfer protein. J. Lipid Res. 1993;34:1255–1274
  17. Zhong SB, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, et al. Increased coronary heart disease in Japanese–American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 1996;97:2917–2923
  18. Hirano K, Yamashita S, Nakajima N, Arai T, Maruyama T, Yoshida Y, et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan-marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler. Thromb. Vasc. Biol. 1997;17:1053–1059
  19. Moriyama Y, Okamura T, Inazu A, Doi M, Iso H, Mouri Y, et al. A low prevalence of coronary heart disease among subjects with increased high density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev. Med. 1998;27:659–687
  20. Patsch JR. Triglyceride-rich lipoproteins and atherosclerosis. Atherosclerosis. 1994;110(Suppl.):S23–S26
  21. Hill SA, McQueen MJ. Reverse cholesterol transport—a review of the process and its clinical implications. Clin. Biochem. 1997;30:517–525
  22. Stein O, Stein Y. Atheroprotective mechanisms of HDL. Atherosclerosis. 1999;144:285–301 Review
  23. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose–response study. Circulation. 2002;105:2159–2165

PII: S0021-9150(03)00137-0

doi: 10.1016/S0021-9150(03)00137-0

Atherosclerosis
Volume 169, Issue 1 , Pages 113-120 , July 2003

Article Tools